\
&
Contact us
The CETPartnership is a co-funded partnership, bringing together private and public stakeholders in the research and innovation ecosystems. CET Partnership aims to create and foster transnational innovation ecosystems and overcome a fragmented research and innovation landscape.
The common vision of the CETPartnership is already manifested in its Strategic Research and Innovation Agenda (SRIA) that has been co-created in a broad engagement process during 2020. This articulates the common goal of:
These goals are set in the framework of the EU Strategic Energy Technology (SET) plan.
Flanders Innovation & Entrepreneurship (VLAIO) is an active member in this co-funded partnership. The funding commitment by VLAIO (excluding the top-up by the European Commission) amounts to €1.000.000. A maximum of three projects is anticipated to be funded. The involvement of at least one private company (SME or large enterprise) based in Flanders is mandatory. A project can be awarded a maximum of €500.000 in funding.
Funding rates vary, from 35-60% for development projects to 60-70% for research projects.
Parties interested to participate in the CET Partnership calls in Flanders are highly recommended to get in touch with the VLAIO contact point, i.e. Frank Verschraegen, to avoid ineligible projects and consortia.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
Ria.debreucker@vlaio.be
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.